Kheiron Medical Technologies, a London, England, UK-based applied science company focused on supporting cancer diagnostics with machine learning, closed a $22m Series A funding.
The round was led by Atomico with participation from Connect Ventures, Greycroft, Hoxton Ventures and EXOR Seeds. As part of this investment, Atomico Principal Irina Haivas will join the board.
The company intends to use the new funding to further scale the clinical validation of Mia™, including conducting a series of large-scale clinical trials and roll-outs in Europe, the United States and Asia to assess and demonstrate the clinical effectiveness and safety of the software.
Led by CEO Dr. Peter Kecskemethy, Kheiron is advancing Mia™, which is designed to analyse standard Full Field Digital mammography (FFDM) images in a breast cancer screening setting, and to assist radiologists in making a vital clinical decision: to recall a woman for further evaluation or not. The software has demonstrated performance in a multi-centre clinical study.
Developed by Kheiron’s team of machine learning specialists, radiologists and imaging industry experts with backgrounds at leading institutions such as Imperial College, The Royal Marsden, University College London, Edinburgh, Oxford, GE and Philips, Mia™ first deployments for live testing and further trials are affiliated with the UK’s National Health Service (NHS) and academic medical centers in the US.